The occurrence of graft-vs-host disease (GvHD) remains one of the major drawbacks limiting the wider application of allogeneic haematopoietic stem cell transplantation (HSCT) preceded by the use of a myeloablative conditioning regimen. GvHD is considered the main cause for transplant-related morbidity and mortality. The median occurrence of clinically significant acute GvHD (grade II-IV) is about 40%, ranging from 10 to 80% depending on the conditioning therapies used and patient-related risk factors. For acute GvHD Grade IV, the treatment-related mortality can exceed 90%. Chronic GvHD represents one of the most common late challenges of allogeneic HSCTF approximately 50% of the patients experience some degree of chronic GvHD ranging from 30 to 80%. Chronic GvHD is the leading cause of non-relapse related deaths.
Taking into account the impact of GvHD on patients' survival and quality of life, the effective prophylaxis of GvHD is of vital importance. Removing T cells by in vitro treatment of the donor marrow is one of the most effective ways to reduce the occurrence and the severity of acute GvHD. Unfortunately, non-specific T-cell depletion increases the rates of graft failure, infections and relapses due to the absence of the beneficial graftvs-leukaemia effect, resulting in an equivalent overall survival. Currently, the most common applied approach for GvHD prevention in transplantations preceded by myeloablative conditioning is the prophylactic use of a regimen with immunosuppressive agents given post transplant: it combines cyclosporine A (CSP) for 6 months (3 mg/kg/day on day À1 through day 10, then oral application tapered off until day þ 180) with a short-course of methotrexate (MTX) (15 mg/qm on day 1; 10 mg/qm on days 3, 6 and 11). Also combinations with 'mini-methotrexate' (5 mg/qm on days 1, 3, 6 and 11) or 'veryshort methotrexate' (omitting the fourth dose on day 11) are used or under clinical investigation. However, it is uncertain whether the addition of corticosteroids provides an advantage by potentially decreasing the occurrence of GvHD as, on the other hand, corticosteroids may augment the risk for infections and consequently may increase mortality. According to the Handbook of the European Group for Bone and Marrow Transplantation (EBMT), the role of methylprednisolone to prevent GvHD is controversial: the results of single studies are ambiguous and no systematic review assessing the role of corticosteroids for preventing GvHD after allogeneic myeloablative HSCT has been published so far.
Therefore, we conducted a comprehensive literature search for randomized controlled trials (with or without blinding) comparing the addition of corticosteroids to a GvHD prophylaxis regimen in adult patients having undergone myeloablative HSCT (either by bone marrow or peripheral blood stem cells). No language restriction was applied. The full search strategy is published in the Cochrane Library. Studies restricted to paediatric patients were excluded. To define the role of commonly used corticosteroids, any kind of drug therapy administered for GvHD prophylaxis in both study arms was considered on the condition that the two study arms differed only with respect to an additional use of corticosteroids. All types and stages of the underlying disease as well as all types of possible HLA-matching (HLA-identical sibling, all extents of HLA-mismatched related and HLA-matched and -mismatched unrelated donor) were considered. For data analyses, dichotomous data, such as cause of death, were analysed by calculating the relative risk for each trial along with a 95% confidence interval (CI). Outcomes with time-to-event data were analysed as hazard ratios (HRs) and presented along with a corresponding 95% CI. The HRs of the single trials were calculated on the basis of individual patient data or, if these were not available, extracted from the publication using well-established methods, for example, using log-rank P-values or Kaplan-Meier survival curves. For time-to-event data with competing risks, that is, events that preclude the occurrence of the failure type of interest, Parmar's method was applied as well and treatment comparisons used log-rank of Kaplan-Meier survival curves or Cox regression analysis, with patients failing from a competing risk treated as lost to follow-up at this time (censored). Where appropriate, results from independent studies were metaanalysed based on a fixed effect model. In meta-analyses with at least four trials, potential publication bias was explored by generating a funnel plot and statistically tested by using a linear regression test. Heterogeneity of treatment effects was assessed using a w 2 test; the significance level was set at Po0.1. To detect statistically significant differences between subgroups, the standard significance level of Po0.05 was chosen. The reliability of pooled results was tested by a priori defined subgroup and sensitivity analyses.
The literature search retrieved 1709 references. 36 references were retrieved as full texts for detailed assessment, of these, 31 studies were excluded. Overall, five randomized controlled trials including 604 patients were included in the review, for study characteristics see Table 1 . [1] [2] [3] [4] [5] For the studies of Deeg et al. 3, 6 and Ruutu et al., 4,7 long-term follow-ups were available. The data of infections of the study of Storb et al. 5, 8 were analysed retrospectively and published separately. We were not able to obtain any additional unpublished data from the authors. All studies included patients with mixed entities of haematological malignancies. None of the studies evaluated nonmyeloablative conditioning regimens; all patients received chemotherapy (mainly cyclophosphamide, alone or in addition either with busulfan and/or fractionated total body irradiation). All but one study used bone marrow of HLA-identical siblings as a source for stem cells.
The main findings of our study are as follows: The linear regression test for funnel plot asymmetry and the various sensitivity analyses performed for all outcomes did not identify statistically significant differences.
Heterogeneity tests revealed statistically significant heterogeneity among the trials for grade I-IV and II-IV for the same subgroups: type of randomization (P ¼ 0.0376 for grade I-IV, P ¼ 0.0147 for grade II-IV) and timing of steroid administration (P ¼ 0.0086 for grade I-IV; P ¼ 0.0139 for grade II-IV). Interestingly, for studies in which the administration of steroids was not overlapping with that of MTX (respectively no MTX was given at all as in the study of Deeg et al.
3 ), the patients showed less acute GvHD grade I-IV and grade II-IV. Storb et al. 5 suspected that the timing of the steroid administration might influence the outcome: in a non-randomized study where patients received prednisone after MTX without overlap, no case of acute GvHD grade IV was documented. This is of special interest as a reduction of particularly high grades of GvHD seems to be desirable as in general patients experiencing grade I have a more favourable prognosisFcredited to the beneficial antileukaemic Figure 1 Forest plot of the overall survival outcome. The filled squares represent the HRs, their size and the weight assigned to the individual study, which is proportional to the inverse variance of the estimate. The horizontal lines show the 95% CIs, the diamond represents the 95% CI for the pooled HR. Values less than 1.0 indicate HRs, which favour the addition of corticosteroids to the immunosuppressive regimen for preventing GvHD. The meta-analysis included five studies with 604 patients (n ¼ number of events; N ¼ number of patients; CI ¼ confidence interval; HR ¼ hazard ratio).
Letters to the Editor effectFcompared to those with grade IV, which is life threatening. However, results of subgroup analyses need to be interpreted with caution as subgroup comparisons across studies are entirely observational and thus have the same limitations as any observational study.
The analysis of chronic GvHD was hampered as the analysis in individual studies was based on different populations; to analyse chronic GvHD, the statistical guidelines for EBMT recommend to restrict the population to those patients who have survived at least until day 100 post transplant as only those are considered to be at risk. However, only two studies analysed their data following this recommendation.
The pooled results for overall survival and disease-free survival show that the advantage of decreased occurrences of acute GvHD grades I-IV and II-IV does not result in an advantage concerning the survival of patients receiving corticosteroids for preventing GvHD. This might be explained by the fact that a sole reduction of low grades of acute GvHD might not increase the survival rate as (a) especially higher grades have a negative impact on survival as explained above and (b) the beneficial graft-vs-leukaemia effect might be eliminated. The latter argument should be reflected in particular in the relapse rates, as less graft-vs-leukaemia effect is supposed to enhance the relapse rates. The conclusion, which can be drawn from the analysis of disease-free survival is, however, limited: the individual studies used various terms for this outcome (eventfree survival, leukemia-free survival, and relapse-free survival) without stating the definitions used.
The occurrence of infectious complications is of special interest as (a) infections still remain an important cause of morbidity and mortality after allogeneic HSCT and (b) corticosteroids are non-specific immunosuppressive agents setting the stage more than others for infectious complications. Owing to the heterogeneity of the reported data and different outcome definitions, we could not perform a meta-analysis and thus, a final judgment about the influence of corticosteroids on the infection rate cannot be given. In addition, an interpretation is complicated by the fact that corticosteroids are used as first-line treatment for acute and chronic GvHD, which might contribute to high rates of infectionsFeven if no corticosteroids are incorporated into the prophylaxis regimen.
In conclusion, there is strong evidence that the administration of corticosteroids to the prophylaxis regimen of GvHD reduces the occurrences of acute GvHD grade I-IV and II-IV. However, there is no evidence for a survival benefit. For the occurrence of infectious complications (under the concomitant use of antibacterial, antiviral and antifungal prophylactic medication), no conclusion can be drawn due to the heterogeneity of the reported data. The subgroup analyses indicated that a 'late' administration of the steroid administration, that is, not overlapping with MTX, might have a positive influence especially on acute GvHD. Further randomized controlled trials are needed to evaluate the impact of the timing of the steroid administration and to estimate the influence of corticosteroids on chronic GvHD analysed within a homogenously defined population and on the infection rate within a homogenously treated population. 
